

SUPPLEMENTARY TABLE A. Intention-to-treat analysis of total serum 25(OH)D and parathyroid hormone concentrations at baseline and over the 25 wk intervention period¹

Measurement and treatment group	Baseline	Week 4	Week 8	Week 12	Week 24	Estimated change after 25 wk adjusting for baseline
Total serum 25(OH)D, nmol/L						
Vitamin D ₃ (25 µg/d), <i>n</i> 30	79 (74, 84)	83 (78, 88)	82 (77, 88)	80 (74, 87)	79 (72, 87)	Ref.
Vitamin D ₂ (25 µg/d), <i>n</i> 25	69 (60, 78)	67 (59, 77)	60 (53, 69)	56 (48, 66)	47 (37, 58)	- 22 (-14, -30) nmol/L ^a
Placebo, <i>n</i> 30	78 (71, 86)	70 (63, 77)	60 (54, 68)	42 (37, 49)	35 (29, 42)	- 43 (-35, -51) nmol/L ^{a,b}
Parathyroid hormone, pg/ml						
Vitamin D ₃ (25 µg/d), <i>n</i> 30	34.0 (29.6, 39.1)	29.7 (25.8, 34.1)	25.8 (22.3, 29.7)	28.0 (23.6, 33.2)	34.6 (29.6, 40.4)	Ref.
Vitamin D ₂ (25 µg/d), <i>n</i> 25	35.9 (30.9, 41.6)	32.3 (28.3, 36.7)	32.4 (27.8, 37.8)	32.2 (26.9, 38.5)	40.8 (34.0, 48.9)	5.4 (-15.8, 31.9) %
Placebo, <i>n</i> 30	35.0 (29.8, 41.2)	30.1 (25.7, 35.3)	29.2 (25.4, 33.6)	31.3 (28.5, 34.4)	40.7 (35.6, 46.6)	12.2 (-10.4, 40.6) %

¹ Geometric mean (95% CI).

^a Significantly different from the vitamin D₃ group after adjustment for baseline concentration, $P < 0.001$.

^b Significantly different from the vitamin D₂ after adjustment for baseline concentration, $P < 0.001$.